NEW YORK (GenomeWeb News) – Life science data analysis firm Selventa has raised $5 million in an equity round, it disclosed in a document filed with the US Securities and Exchange Commission this week.
The company did not say how the funds would be used and did not disclose participants in the financing, though it said nine people invested in the round.
A company official was not available for comment, a spokesperson said.
Based in Cambridge, Mass., Selventa was founded in 2002 and was formerly called Genstruct. On its website it calls itself "a personalized healthcare company that helps pharmaceutical and biotechnology partners find optimal treatments for the right patients through early patient stratification and portfolio optimization."
Its flagship technology, called Genstruct Technology Platform, uses in silico reverse causal reasoning to translate large-scale data "into meaningful, testable molecular mechanisms," it said.